-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 26, the CDE official website issued a notice that six anti-tumor varieties were selected after reviewing the list of varieties, which can be directly revised to increase the indications for children and the usage and dosage of the drug.
We are now seeking opinions from the industry and the society.
The 6 anti-tumor varieties are: cisplatin, ifosfamide, mesna, azathioprine, asparaginase and vindesine, involving Hengrui, Qilu, Shuanglu Pharmaceutical, Baiyunshan, Yangtze River, etc.
Table 1: The specific situation of the revised opinions on adding children's medication information to the second batch of marketed drug inserts
Source: CDE official website, compiled by Mi Nei.
Table 2: The situation of the enterprises involved in the corresponding specifications of the 6 varieties
Source: One-click search on Mi Nei.
According to data from Meinenet, the above 6 anti-tumor drugs are all in the 2020 National Medical Insurance Catalogue, and domestic giants such as Hengrui, Qilu, Shuanglu Pharmaceutical, Baiyunshan, and Yangzijiang have layouts.
In 2019, the sales scale of ifosfamide injection (including 0.
Vindesine injection (1mg) has a terminal sales of 120 million yuan in public medical institutions in China in 2019.
For a long time, my country's children's medicines have faced problems such as difficult research and development, fewer varieties of medicines, and lack of proprietary dosage forms.
